BHIVA webinar - ANCHOR Study: results and their implications

Conferences and Events > Previous Conferences and Events > 2022 Conferences and Events >

BHIVA webinar - ANCHOR Study: results and their implications

Date and Time: Wednesday 28th September 2022, 16:30 – 18:00

Format: VIRTUAL

People with HIV are at higher risk of HPV-related conditions, including anal cancer. CROI 2022 saw the presentation of the Anal Cancer HSIL Outcomes Research (ANCHOR) Study which compared active monitoring with treatment for people with pre-cancerous lesions detected at anoscopy. Treatment led to an almost 60% reduction in anal cancer incidence and the trial was stopped early.

However, many questions remain including the feasibility, cost-effectiveness and longer-term benefit of this strategy, not to mention the impact of HPV vaccination. This special BHIVA session brought together experts in the field to summarise the ANCHOR findings, review ongoing trials in this area and discuss the implications for research and care.

The webinar and PDF presentations are available to view below.

Watch the webinar

Download PDF presentations

Chairs:
Simon Collins, HIV i-Base
Tristan Barber, Royal Free London NHS Trust

The ANCHOR Study
Iain Reeves, Homerton University Hospital, London

Perspective of HPV in women
Deirdre Lyons, Imperial College Healthcare NHS Trust

Management of screening and treatment of anal pre-cancer/cancer in people with HIV
Tamzin Cuming, Homerton University Hospital, London

SEPAC and future strategies for AIN screening
Richard Gilson, Chief Investigator, SEPAC study, University College London

Speaker biographies

The ANCHOR Study
Iain Reeves, Homerton University Hospital, London
Iain Reeves has been a consultant in London for over 10 years and is lead clinician for HIV at the Homerton Hospital. He has special interests in the sexual health of MSM and in mental health and is a principal investigator on a number of HIV and sexual health studies. From 2019 Dr Reeves was Chair of the BHIVA Conferences Subcommittee for a three-year term and has been a member of the BHIVA Treatment Guidelines Writing Group since 2014. He was chair of the HIV-2 treatment guidelines writing group, lead for the “what to start” section of the 2022 HIV-1 treatment guidelines and led on three sections of the BHIVA clinical standards 2018. He was re-elected as a BHIVA trustee to serve on the Executive Committee from 2018–2021. Dr Reeves was elected as Honorary Treasurer to serve from 2020 to 2023.

Perspective of HPV in women
Deirdre Lyons, Lead Colposcopy/ CSPL ICHT, DCCIO, London SQAS PCA, President Elect BSCCP, Imperial College Healthcare NHS Trust
Deirdre Lyons is a gynaecologist with a special interest in multizonal disease and also undertakes High Resolution Anoscopy at Imperial College Healthcare NHS Trust. She has experience of management of complex lower genital tract intra-epithelial neoplasia and is on the BSCCP Working group generating a consensus opinion for assessment and management of complex lower genital tract disease. Miss Lyons is also part of the Expert Working Group, that works with the NHS to generate suitable coding for procedures and have had initial discussions on the creation of a MZIN code to ensure clinics are funded appropriately. She has been parts of two therapeutic vaccine trials and more recently took part in iknife trial and post- treatment HPV vaccine trial. She is also interested in digital health and has completed PgDip in Digital Healthcare Leadership through the NHS Digital Academy.

Management of screening and treatment of anal pre-cancer/cancer in people with HIV
Tamzin Cuming, Homerton University Hospital, London
Tamzin Cuming is a consultant colorectal surgeon who has specialised in the management of anal neoplasia. She is the Vice President of the International Anal Neoplasia Society and the lead of the largest anal neoplasia service in the UK at Homerton Hospital in London. Tamzin was educated at a state grammar school then Cambridge and Guys & St Thomas' Hospitals in London. Her SpR training on the South and North East Thames rotations was extended for a period of flexible training while she had her three children. She obtained her FRCS in General Surgery in 2010 and Masters in Surgical Education from Imperial in 2012 along with her CCT after a laparoscopic fellowship. She began her training in high resolution anoscopy (HRA) as a consultant at Homerton in 2013. She is the current Chair of the Women in Surgery Forum at the Royal College of Surgeons of England and is pursuing a part time PhD on the Treatment of Anal Neoplasia at the University of Amsterdam.

SEPAC and future strategies for AIN screening
Richard Gilson, Chief Investigator, SEPAC study, University College London
Richard Gilson is Professor of Sexual Health and HIV Medicine at UCL and Honorary Consultant at the Mortimer Market Centre, Central and North West London NHS Foundation Trust. He is Director of the Centre for Clinical Research in Infection and Sexual Health, which is part of the UCL Institute for Global Health. His research includes a programme of work on HPV infection, currently developing a screening strategy for the detection of anal pre-cancer in men who have sex with men living with HIV infection, funded by Cancer Research UK. He has a longstanding interest in hepatitis B and C virus infections, investigating both novel treatment approaches as well as prevention. Since the beginning of the COVID-19 pandemic, he has worked closely with colleagues at UCL and UCLH on treatment trials, and epidemiological studies both in healthcare settings and in the community. He is a member of the Commission on Human Medicines at the MHRA and a member of expert working groups on COVID-19 therapeutics.